



**Liquidia Technologies Contact:**

Elle Pishny

919-328-4361

[elle.pishny@liquidia.com](mailto:elle.pishny@liquidia.com)

## **LIQUIDIA TECHNOLOGIES RETAINS TOP INDUSTRY TALENT TO LEAD MANUFACTURING EFFORTS**

*Company Appoints Dr. Thomas Templeman, Senior Vice President*

**RESEARCH TRIANGLE PARK, NC – June 11, 2009** – Liquidia Technologies Inc. today announced it has appointed Dr. Thomas Templeman as the company’s Senior Vice President, Integrated Supply Chain. Liquidia is a leader in the development of rationally designed nanoparticles for delivery of small molecule and biological agents to enable breakthroughs in vaccines, inhaled therapeutics, and siRNA-based therapeutics.

“We are very pleased to welcome Dr. Templeman to Liquidia as we continue to expand and strengthen our capabilities in manufacturing,” said Neal Fowler, CEO of Liquidia. “Dr. Templeman brings to Liquidia a diverse array of clinical and commercial manufacturing experience. He also has extensive knowledge in regulatory compliance and shares our passion for bringing safer and more effective therapies to market.”

Dr. Templeman comes to Liquidia from Centocor Biologics, an operating company of Johnson & Johnson and manufacturing site that supports the Centocor family of biologic products. As General Manager, Dr. Templeman was responsible for establishing, managing, and updating regulated production facilities, including the implementation of operational and quality control systems.

“This is a very exciting opportunity for me, as the future of medicine will be defined by the availability of highly targeted therapies that provide greater safety and efficacy for patients,” said Dr. Templeman. “Liquidia is clearly a leader in the field of nanoparticle-based therapies and I am honored to have the opportunity to help advance the company towards a new phase of product development.”

Following his Postdoctoral Fellowship in Harvard University’s Department of Cellular and Developmental Biology in 1989, Dr. Templeman gained extensive experience in R&D and manufacturing processes at Vysis, Imagenetics, Gene-Trak, Ortho Clinical Diagnostics and most recently at Centocor Biologics. Dr. Templeman’s areas of expertise include the management of technical operations and the development, scale-up, and improvement of R&D processes to production output levels.

**About Liquidia** - Liquidia Technologies Inc. is a privately-held nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Within life sciences, Liquidia is focused on the development of rationally designed nanoparticles for various therapeutic applications including inhaled therapeutics, vaccines, and siRNA delivery. Materials science applications include nanoscale patterned optical films for use in display technologies and photovoltaic devices. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. For additional information, please visit [www.liquidia.com](http://www.liquidia.com).